Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Capital Employed (2020 - 2025)

Tarsus Pharmaceuticals has reported Return on Capital Employed over the past 6 years, most recently at 0.17% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.17% for Q4 2025, up 24.0% from a year ago — trailing twelve months through Dec 2025 was 0.17% (up 24.0% YoY), and the annual figure for FY2025 was 0.21%, up 29.0%.
  • Return on Capital Employed for Q4 2025 was 0.17% at Tarsus Pharmaceuticals, up from 0.22% in the prior quarter.
  • Over the last five years, Return on Capital Employed for TARS hit a ceiling of 0.02% in Q2 2021 and a floor of 0.62% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 0.28% (2022), compared with a mean of 0.31%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -33bps in 2023 and later rose 28bps in 2025.
  • Tarsus Pharmaceuticals' Return on Capital Employed stood at 0.07% in 2021, then plummeted by -312bps to 0.29% in 2022, then plummeted by -115bps to 0.62% in 2023, then skyrocketed by 35bps to 0.41% in 2024, then soared by 58bps to 0.17% in 2025.
  • The last three reported values for Return on Capital Employed were 0.17% (Q4 2025), 0.22% (Q3 2025), and 0.24% (Q2 2025) per Business Quant data.